The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half […] The post Brepocitinib Phase 2 trial doses first cutaneous sarcoidosis patients appeared first on Sarcoidosis News.
